

# **Multilex Bulletin – December 2019**

The Multilex Bulletin is an indication of notable changes made to the Multilex database. It also provides general information and advance warnings of changes for future months. Changes to product name are expressed in the form of the Multilex Preferred Display Name. Customers using other naming conventions may not see the changes as listed. Visibility of changes is dependent on the current data being loaded into your system and the specified element being available via your interface.

This document is not a list of all changes to the Multilex database.

The Multilex Bulletin is also available at www.fdbhealth.co.uk

## **Dm+d/Manufacturer Changes**

The following products have been amended in line with the Dictionary of Medicines and Devices (dm+d) and/or the manufacturers' Summary of Product Characteristics (SPC):

#### Valcyte

Valcyte 50mg/ml oral solution now reads: Valcyte 50mg/ml powder for oral solution

#### Valganciclovir

Valganciclovir 50mg/ml oral solution sugar-free now reads: Valganciclovir 50mg/ml powder for oral solution sugar-free

## **Other Changes**

### **Controlled Drug Schedule 3 supply quantities**

Changes have been made so that all Schedule 3 Controlled Drugs default supply values align with recommendations for a maximum 30-day supply from Medicines, Ethics and Practice.

This predominately affects reclassified products where the standard pack sizes now exceed the expected 30day supply. Quantity and supply values continue to be manually adjustable.